Show results for
Refine by
Chronic Heart Failure Articles & Analysis
5 articles found
*Synthetic Vericiguat Acting as a stimulator of soluble guanylate cyclase (sGC), Vericiguat catalyzes the synthesis of intracellular cyclic guanosine monophosphate (cGMP) and increases intracellular cGMP levels, thereby relaxing smooth muscle and vasodilating for heart failure. The drug, developed by Bayer AG and approved by the FDA in 2021, is the first to be ...
Sub codes of 150.3 are: I50.30: Unspecified diastolic (congestive) heart failure I50.31: Acute diastolic (congestive) heart failure I50.32: Chronic diastolic (congestive) heart failure I50.33: Acute on chronic diastolic (congestive) heart ...
Recent clinical trials investigating sodium-glucose cotransporter 2 inhibitors (SGLT2i) have highlighted that this drug is highly effective in treating patients with heart failure with preserved ejection fraction (HFpEF). HFpEF is a complex disease which accounts for more than half of all heart failure (HF) hospital admissions ...
We include devices under investigation for ADHF but did not include devices for the treatment of cardiogenic shock, such as mechanical circulatory support, or durable left ventricular assist devices for the management of chronic heart failure. Dilators (D) The veins of the abdomen normally have a high capacity to store and mobilize blood. ...
February 1, Prague/ Udalosti. The epidemic called “Chronic Heart Failure” affects up to half a million Czechs. An innovation being tested at Prague’s Na Homolce Hospital could be a turning point in the care of these patients. A special implant adjusts the shape of the left ventricle, which may allow the heart to ...